Table 1.

Trial factors associated with complete BMEC

Trial Characteristics		No. Trials with Complete BMEC/Total	Percent	P-valuea
Industry funding of trial	Yes	141/361	39.1	P = 0.02
	No	27/101	26.7
Cooperative group trial	Yes	35/112	31.3	P = 0.20
	No	132/348	37.9
Enrollment start year	1995–2000	4/8	50	P  = 0.02
	2001–2005	41/90	45.6
	2006–2010	96/258	37.2
	2011–2015	26/102	25.5
Disease siteb	Breast	32/75	42.7	P  < 0.001
	Gastrointestinal	43/76	56.6
	Genitourinary	35/55	65.5
	Head & Neck	4/23	17.4
	Melanoma	5/20	25.0
	Thoracic	18/95	18.9
Treatment modalityc	Systemic therapy	137/334	41.0	P  = 0.01
	Radiotherapy	1/6	16.7
	Surgery	1/2	50.0
	Supportive care	26/112	23.2
Systemic therapy subgroupd	Targeted therapy	106/257	41.2	P = 0.88
	Cytotoxic chemotherapy	31/77	40.3
Completed planned accrual	Yes	90/240	37.5	P = 0.56
	No	37/108	34.3
Trial success (primary endpoint met)	Yes	72/198	36.4	P = 0.53
	No	70/177	39.5

^a P-value reflects Pearson’s chi-squared tests for all except enrollment start year, for which P-value reflects results of binary logistic regression analysis by year.

^bLimited to trials with a defined single disease site.

^cPrimary intervention as part of the randomization. Systemic therapy includes cytotoxic chemotherapy, targeted systemic agents, and similar, with primary endpoint aimed at improved disease-related outcomes. Supportive care trials aimed to reduce disease- or treatment-related toxicity.

^dSystemic therapy trials subdivided further into those assessing a targeted therapy (including small molecule inhibitors, monoclonal antibodies, and similar) and those assessing cytotoxic chemotherapy.